

1 **Effects of H3 and H4 histones acetylation and bindings of CREB binding protein**  
2 **and p300 at the promoter on hepatic expression of  $\gamma$ -glutamyltransferase gene in a**  
3 **streptozotocin-induced moderate hypoinsulinemic rat model**

4

5 Tomoyuki Tanaka<sup>1</sup>, Takahiro Mizuno<sup>2</sup>, Tomoyuki Nakagawa<sup>1,2</sup>, Takashi Hayakawa<sup>1,2</sup>,  
6 Masaya Shimada<sup>1,2\*</sup>

7

8 <sup>1</sup> Division of Life Science for Food, Department of Life Science and Chemistry,  
9 Graduate School of Natural Science and Technology, Gifu University, 1-1 Yanagido,  
10 Gifu-shi, Gifu 501-1193, Japan

11 <sup>2</sup> Department of Applied Life Science, Faculty of Applied Biological Sciences, Gifu  
12 University, 1-1 Yanagido, Gifu-shi, Gifu 501-1193, Japan

13

14 \*Corresponding author. Department of Applied Life Science, Faculty of Applied  
15 Biological Sciences, Gifu University, 1-1 Yanagido, Gifu-shi, Gifu 501-1193, Japan

16 Phone/Fax: 81-58-293-2861

17 E-mail address: mshimada@gifu-u.ac.jp

18

19 **Short title**

20 Hepatic regulation of *Ggt* in moderate hypoinsulinemia

21

22 **Summary**

23 Gamma-glutamyltransferase (GGT), a marker of liver disease, has been shown to be  
24 associated with increased risk of diabetes and relative insulin secretion deficiency.

25 However, the mechanism of hepatic *Ggt* regulation has not been explored fully. In this  
26 study, we made a concerted effort to understand the mechanism by investigating the  
27 effects of acetylation of histones H3 and H4, and bindings of histone acetyltransferases,  
28 CREB binding protein (CBP) and p300, at the *Ggt* promoter on the regulation of the  
29 expression *Ggt* gene in the livers of streptozotocin (STZ)-induced moderate  
30 hypoinsulinemia rat model. The rats treated with STZ showed remarkably higher serum  
31 GGT level and hepatic *Ggt*/GGT expression than the untreated control rats. Furthermore,  
32 the acetylation of histones H3 and H4, and the binding of CBP not p300 at the *Ggt*  
33 promoter regions were significantly higher in the livers of STZ rats than those of the  
34 control rats. These results suggest that an enhanced hepatic expression of *Ggt* is  
35 associated with increased acetylation of histones H3 and H4 and CBP binding at the *Ggt*  
36 promoter in STZ-induced moderate hypoinsulinemic rats.

37

38

39

40

41 **Keywords**

42 Acetylated histone; CBP; GGT; Liver; Streptozotocin

43

44

45 **Main body**

46       Gamma-glutamyltransferase (GGT) plays a key role in the extracellular  
47 catabolism of the major antioxidant, glutathione. Its increased circulating level by  
48 oxidative stress has been reported as a marker for hepatic injuries, such as liver  
49 dysfunction induced by excessive alcohol intake (Kunutsor 2016). Furthermore, human  
50 observational studies via a systematic review have reported that the circulating levels of  
51 GGT are associated with an increased risk of type 2 diabetes (Kunutsor *et al.* 2014). It  
52 has also been shown that the increased levels of GGT in the blood are related to the  
53 attenuated function of pancreatic  $\beta$ -cells in young obese subjects (Wang *et al.* 2013).  
54 However, in adult patients with type 1 diabetes, Arkkila *et al.* (2001) could not establish  
55 its association with diabetes duration, body mass index, and hemoglobin A1c instead  
56 showed its association with retinopathy and neuropathy. Collectively, these studies  
57 suggest that the elevated circulating levels of GGT could be associated with relative but  
58 not absolute insulin secretion deficiency. Furthermore, an *in vitro* study has shown that  
59 insulin treatment decreases the expression of the *GGT* gene in human hepatocytes,  
60 HepG2 (Honma *et al.* 2017), suggesting that increased insulin secretion downregulates  
61 the expression of the *GGT* gene in the liver. However, the regulation of the expression  
62 of *GGT* is currently poorly understood. Therefore, we speculate that a better  
63 understanding of the regulatory mechanisms of hepatic *GGT* expression under relatively  
64 deficient insulin secretion could help develop the key strategies for the management of  
65 diabetes.

66       Gene expression is regulated by histone modifications, such as acetylation and  
67 methylation, and transcription factors (Schübeler *et al.* 2004). In particular, enhanced  
68 gene expression is closely related to the hyperacetylation of histones H3 and H4 in the

69 euchromatin region of the genome (Roh *et al.* 2005). *In vivo* studies using type 2  
70 diabetic mice (db/db) models have shown an increase in the hepatic expression of  
71 gluconeogenic genes, such as phosphoenolpyruvate carboxykinase 1 (*Pck1*), and  
72 acetylation of histone H3 on the gluconeogenic genes (Ravnskjaer *et al.* 2013). In  
73 addition, Suzuki *et al.* (2015) have reported that hepatic expression of fatty acid  
74 synthase gene and acetylation of histones H3 and H4 on the fatty acid synthase gene are  
75 increased in SHR/NDmc-cp rats, a spontaneously hypertensive, obese and diabetic  
76 model of rats. However, the effects of histone acetylation on the expression of the *Ggt*  
77 gene in the liver of hypoinsulinemic models have not yet been reported.

78         In the present study, we examined the effects of acetylation of histones H3 and  
79 H4 on the *Ggt* promoter in streptozotocin (STZ)-induced moderate (not severe)  
80 hypoinsulinemia rat model on the expression of the *Ggt* gene. Furthermore, it is known  
81 that CREB binding protein (CBP) and p300, the histone acetyltransferases bind to  
82 acetylated histones and nuclear transcription factors to mediate the recruitment of the  
83 transcriptional complex (Chan and La Thangue 2001). Therefore, to elucidate their role  
84 in regulating the expression of the *GGT* gene, we investigated whether the bindings of  
85 CBP and p300 to the *Ggt* promoter are altered in the liver of the hypoinsulinemic rats.

86         Six-week-old male Wistar/ST rats were purchased from Japan SLC (Shizuoka,  
87 Japan) and divided into control and STZ groups. Control group rats (n=6) were  
88 intraperitoneally administered a single dose of saline. To induce moderate  
89 hypoinsulinemia, STZ group rats (n=7) were intraperitoneally administered a single low  
90 dose of STZ (40 mg/kg body weight; FUJIFILM Wako Pure Chemical Corporation,  
91 Osaka, Japan) dissolved in saline, prepared immediately (within 5 min) before the  
92 administration. At 5 d after treatment, we confirmed that the random serum glucose  
93 level in the STZ group rats was within the range of 300–500 mg/dl. The rats were given

94 free access to a laboratory chow diet (MF; Oriental Yeast, Tokyo, Japan) and water  
95 throughout the acclimation and experimental periods. At 30 d after treatment, the rats  
96 were fasted for 4 h and euthanized via cardiac puncture under isoflurane inhalation  
97 anesthesia, and blood and liver tissue were collected for subsequent assays. All animal  
98 care and experimental procedures were approved by the Gifu University Animal Care  
99 and Usage Committee.

100 Concentrations of serum biochemical parameters (glucose, triglyceride, insulin,  
101 glucagon, glutamic pyruvic transaminase (GPT), and GGT) were measured using  
102 commercial kits (Glucose CII Test Wako kit, Triglyceride E-test Wako kit, LBIS  
103 Insulin-Rat ELISA kit (U-E type), Transaminase CII Test kit; all from FUJIFILM Wako  
104 Pure Chemical Corporation, Glucagon enzyme immunoassay (EIA) Kit; Yanaihara  
105 Institute, Shizuoka, Japan, and GGT Activity Colorimetric Assay Kit; Bio Vision, CA,  
106 USA). Hepatic triglycerides were determined following the method described by  
107 Shimada *et al.* (2019).

108 Hepatic total RNA was extracted and converted to cDNA using commercial kits.  
109 Real-time PCR was conducted as described by Shimada *et al.* (2019). The primers used  
110 were as follows: *Pck1* (5'-GATGACATTGCCTGGATGAA-3',  
111 5'-AACCGTTTTCTGGGTTGATG-3'), *Gpt* (5'-CAGGAGGGCACCTATCATT-3',  
112 5'-TTGGCATGGAAGTGAAGTACTGAG-3'), *Ggt*  
113 (5'-ACAGCCCAGATTGTGAAAGAC-3', 5'-TCCGCACGATAGTTGTTAAGG-3'),  
114 and *36b4* (5'-CGAGAAGACCTCTTTCTTCCAA-3',  
115 5'-AGTCTTTATCAGCTGCACATCG-3'). Relative mRNA levels were normalized to  
116 the housekeeping gene *36b4* using the  $2^{-\Delta\Delta CT}$  method.

117 Preparation of hepatic protein lysates and subsequent immunoblotting were  
118 conducted following Ichigo *et al.* (2019). The primary antibodies used were anti-GGT

119 antibody (Gene Tex, CA, USA) and anti-TATA-binding protein (TBP; GeneTex). TBP  
120 was used as a loading control.

121 Hepatic chromatin and subsequent chromatin immunoprecipitation (ChIP) were  
122 prepared following the method described by Shimada *et al.* (2019). The antibodies used  
123 were as follows: anti-acetyl-histone H3 (Millipore, CA, USA), anti-acetyl-histone H4  
124 (Millipore), CBP (Santa Cruz Biotechnology, TX, USA), p300 (Santa Cruz  
125 Biotechnology), or normal rabbit/mouse IgG (FUJIFILM Wako Pure Chemical  
126 Corporation). Immunoprecipitated DNA and input DNA were subjected to real-time  
127 PCR. The primers, which amplified three *Ggt* promoter regions, were as follows:  
128 *Ggt*-900 (5'-CCTTTGAAGGGTTTTCCAGTG-3',  
129 5'-TCCTGGTGATGTCCACAGTTT-3'), *Ggt*-700  
130 (5'-CTTGTTGACCTTGGGCATCT-3', 5'-GGACAGTTCCTTTGCCTCTTT-3'), and  
131 *Ggt*-350 (5'-TGGAGATTCCAGACAGCATAGA-3',  
132 5'-TCACACAGATCTGAAGCCACTT-3'). ChIP signals were normalized to the  
133 corresponding input signals using the  $2^{-\Delta\Delta CT}$  method.

134 Values are expressed as mean  $\pm$  SEM. Differences between the two groups were  
135 evaluated using the Student's *t*-test.  $P < 0.05$  indicated statistical significance.

136 The body weight gain, levels of hepatic triglycerides and serum insulin were  
137 significantly lower, whereas the levels of serum glucose, triglycerides, glucagon,  
138 GPT— another marker for hepatic damage, and GGT were significantly higher in STZ  
139 rats than in control rats (Table 1).

140 Hepatic expression levels of *Pck1*, *Gpt*, and *Ggt* genes were significantly higher  
141 in STZ rats than in the control rats (Fig. 1A). Similarly, the hepatic expression level of  
142 GGT was significantly higher in STZ rats than in the control rats (Fig. 1B).

143 Moreover, hepatic acetylation of histone H3 on the -900 bp promoter region,

144 acetylation of histone H4 on the -900 bp, -700 bp, and -350 bp promoter regions, and  
145 binding of CBP to the -900 bp and -700 bp promoter regions in the *Ggt* gene were  
146 significantly higher in the STZ rats than the control rats (Fig. 1C, 1D, and 1E), whereas  
147 binding of p300 to the promoter regions did not differ significantly between the two  
148 groups (Fig. 1F).

149 In this study, we observed higher hepatic expression of *Ggt*/GGT and serum level  
150 of GGT in the STZ rats than in control rats, which suggested that though GGT is  
151 expressed in many tissues, the increased GGT level in the blood could be partially  
152 attributable to enhanced hepatic expression of *Ggt*/GGT.

153 For the first time, this study revealed that the binding of CBP and the acetylation  
154 of histones H3 and H4 were increased in the promoter regions of *Ggt* in the liver of the  
155 STZ-induced moderate hypoinsulinemic rats; however, it remains unclear which signals  
156 contribute to the enhanced hepatic expression of the *Ggt* gene. Shoukry (1988) showed  
157 that the treatment with insulin reduces the GGT levels in the blood of STZ-induced type  
158 1 diabetic rats. In addition, Honma *et al.* (2017) reported that insulin treatment  
159 decreases the expression of *Ggt* and *Gpt* genes and gluconeogenic enzyme genes, such  
160 as *Pck1*, and acetylation of histones H3 and H4 on the *Gpt* and *Pck1* genes in HepG2  
161 cells. Moreover, He *et al.* (2009) demonstrated that insulin treatment represses *Pck1*  
162 expression via phosphorylation of CBP at serine 436, which inactivates CBP in mouse  
163 liver. Collating the findings of this study with those of previously reported studies, it  
164 can be inferred that moderate hypoinsulinemia could be associated with  
165 dephosphorylation of CBP at serine 436 and recruitment of CBP to increase acetylation  
166 of histones H3 and H4 in the promoter region of *Ggt*. However, this should be validated  
167 through further studies by investigating the effects of insulin administration to  
168 STZ-induced moderate hypoinsulinemic rats.

169 Furthermore, it is noteworthy that the moderate hypoinsulinemic rats exhibited  
170 higher serum glucagon levels in this study. It has been described that glucagon increases  
171 the recruitment of CBP to hepatic gluconeogenic genes under fasting conditions via  
172 activation of the cAMP/PKA/CREB signaling pathway (Altarejos and Montminy 2011).  
173 Considering these findings, it is speculated that a combination of lower insulin and  
174 higher glucagon could induce expression of the *Ggt* gene via enhanced recruitment of  
175 CBP to the *Ggt* gene; however, this hypothesis warrants further investigation.

176 Though the present study demonstrated the enhanced expression of hepatic  
177 *Ggt*/GGT in STZ-induced moderate hypoinsulinemic rats, the relationship between  
178 moderate hypoinsulinemia and GGT remains controversial. Studies in humans have  
179 reported that elevated GGT levels could predict the development of insulin resistance  
180 (Lee *et al.* 2013; Ryoo *et al.* 2014). Thus, further studies should chronologically  
181 investigate circulating levels of GGT accompanied by pancreatic  $\beta$ -cell exhaustion  
182 using young Goto-Kakizaki type 2 diabetic rats, which exhibit mild hyperglycemia with  
183 a reduction of  $\beta$ -cell mass at an early stage (Movassat *et al.* 1995).

184 In conclusion, we have demonstrated that enhanced hepatic *Ggt* expression is  
185 associated with increased CBP binding and histone H3 and H4 acetylation on the *Ggt*  
186 gene promoter regions in STZ-induced moderate hypoinsulinemic rats.

187

188

189

190

## 191 **Conflict of Interest**

192 The authors declare that there are no conflicts of interest to declare in the

193 publication of this study.

194

195 **Acknowledgments**

196 This work was supported by JSPS KAKENHI Grant number JP18K02237.

197

198

199 **References**

- 200 ALTAREJOS JY, MONTMINY M: CREB and the CRTC co-activators: Sensors for  
201 hormonal and metabolic signals. *Nat Rev Mol Cell Biol* 12: 141-51, 2011.
- 202 ARKKILA PE, KOSKINEN PJ, KANTOLA IM, RÖNNEMAA T, SEPPÄNEN E,  
203 VIKARI JS: Diabetic complications are associated with liver enzyme activities in  
204 people with type 1 diabetes. *Diabetes Res Clin Pract* 52: 113-118, 2001.
- 205 CHAN HM, LA THANGUE NB: p300/CBP proteins: HATs for transcriptional bridges  
206 and scaffolds. *J Cell Sci* 114: 2363-2373, 2001.
- 207 KUNUTSOR SK, ABBASI A, ADLER AI: Gamma-glutamyl transferase and risk of  
208 type II diabetes: an updated systematic review and dose-response meta-analysis. *Ann*  
209 *Epidemiol* 24: 809-816, 2014.
- 210 KUNUTSOR SK: Gamma-glutamyltransferase-friend or foe within? *Liver Int* 36:  
211 1723-1734, 2016.
- 212 HE L, SABET A, DJEDJOS S, MILLER R, SUN X, HUSSAIN MA, RADOVICK S,  
213 WONDISFORD FE: Metformin and insulin suppress hepatic gluconeogenesis through  
214 phosphorylation of CREB binding protein. *Cell* 137: 635-646, 2009.
- 215 HONMA K, KAMIKUBO M, MOCHIZUKI K, GODA T: Insulin-induced inhibition of  
216 gluconeogenesis genes, including glutamic pyruvic transaminase 2, is associated with  
217 reduced histone acetylation in a human liver cell line. *Metabolism* 71: 118-124, 2017.
- 218 ICHIGO Y, TAKESHITA A, HIBINO M, NAKAGAWA T, HAYAKAWA T, PATEL  
219 D, FIELD CJ, SHIMADA M: High-fructose diet-induced hypertriglyceridemia is  
220 associated with enhanced hepatic expression of ACAT2 in rats. *Physiol Res* 68:  
221 1021-1026, 2019.
- 222 LEE SY, SUNG E, CHANG Y: Elevated serum gamma-glutamyltransferase is a strong  
223 marker of insulin resistance in obese children. *Int J Endocrinol* 2013: 578693, 2013.

224 MOVASSAT J, SAULNIER C, PORTHA B: Beta-cell mass depletion precedes the  
225 onset of hyperglycaemia in the GK rat, a genetic model of non-insulin-dependent  
226 diabetes mellitus. *Diabete Metab* 21: 365-370, 1995.

227 RAVNSKJAER K, HOGAN MF, LACKEY D, TORA L, DENT SYR, OLEFSKY J,  
228 MONTMINY M: Glucagon regulates gluconeogenesis through KAT2B- and  
229 WDR5-mediated epigenetic effects. *J Clin Invest* 123: 4318-4328, 2013.

230 ROH TY, CUDDAPAH S, ZHAO K: Active chromatin domains are defined by  
231 acetylation islands revealed by genome-wide mapping. *Genes Dev* 19: 542-552, 2005.

232 RYOO JH, OH CM, KIM HS, PARK SK, CHOI JM: Clinical association between  
233 serum gamma-glutamyltransferase levels and the development of insulin resistance in  
234 Korean men: a 5-year follow-up study. *Diabet Med* 31: 455-461, 2014.

235 SCHÜBELER D, MACALPINE DM, SCALZO D, WIRBELAUER C,  
236 KOOPERBERG C, VAN LEEUWEN F, GOTTSCHLING DE, O'NEILL LP,  
237 TURNER BM, DELROW J, BELL SP, GROUDINE M: The histone modification  
238 pattern of active genes revealed through genome-wide chromatin analysis of a higher  
239 eukaryote. *Genes Dev* 18: 1263-1271, 2004.

240 SHIMADA M, ICHIGO Y, SHIROUCHI B, TAKASHIMA S, INAGAKI M,  
241 NAKAGAWA T, HAYAKAWA T: Treatment with myo-inositol attenuates binding of  
242 the carbohydrate-responsive element-binding protein to the ChREBP- $\beta$  and FASN  
243 genes in rat nonalcoholic fatty liver induced by high-fructose diet. *Nutr Res* 64: 49-55,  
244 2019.

245 SHOUKRY MI: Gamma glutamyl transferase in diabetic rats. The effect of insulin  
246 treatment. *Acta Diabetol Lat* 25: 299-302, 1988.

247 SUZUKI T, MURAMATSU T, MORIOKA K, GODA T, MOCHIZUKI K: ChREBP  
248 binding and histone modifications modulate hepatic expression of the Fasn gene in a

249 metabolic syndrome rat model. *Nutrition* 31: 877-883, 2015.

250 WANG L, ZHANG J, WANG B, ZHANG Y, HONG J, ZHANG Y, WANG W, GU W:

251 New evidence for an association between liver enzymes and pancreatic islet beta-cell

252 dysfunction in young obese patients. *Endocrine* 44: 688-695, 2013.

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274 **Table 1.** Physiological and biochemical parameters in control and STZ-induced

275 moderate hypoinsulinemic rats

276

	Control	STZ
Body weight gain (g)	132 ± 6	82 ± 7 ***
Liver		
Weight (g)	12.6 ± 0.4	12.1 ± 0.4
Triglycerides (mg/g liver)	53.6 ± 4.3	35.9 ± 2.1 **
Serum		
Glucose (mg/dl)	141 ± 6	349 ± 31 ***
Triglycerides (mg/dl)	48.7 ± 3.6	74.8 ± 10.0 *
Insulin (pg/ml)	564 ± 154	66 ± 26 **
Glucagon (pg/ml)	369 ± 35	552 ± 41 **
GPT (U/l)	11.1 ± 0.5	18.1 ± 1.5**
GGT (U/l)	1.25 ± 0.02	1.86 ± 0.13**

277

278 Values are expressed as means ± standard error of the mean (n = 6–7). \*\*\*  $P < 0.001$ ;

279 \*\*  $P < 0.01$ ; \*  $P < 0.05$ , significantly different from the control group (Student's *t*-test).

280 Control, control rats treated with vehicle; STZ, moderate hypoinsulinemic rats treated

281 with streptozotocin; GPT, glutamic pyruvic transaminase; GGT,  $\gamma$ -glutamyltransferase.

282

283

284 **Figure Legends**

285 **Fig. 1.** Hepatic expression of *Ggt*/GGT, acetylation of histones H3 and H4, and  
286 bindings of CBP and p300 to the *Ggt* gene promoter in control and STZ-induced  
287 moderate hypoinsulinemic rats.  
288  
289 (A) Expression levels of *Pck1*, *Gpt*, and *Ggt* genes were analyzed using real-time  
290 quantitative PCR. Expression levels were normalized to the expression of *36b4*. (B)  
291 Expression level of GGT was detected using Immunoblot. The expression level was  
292 normalized to the expression of TBP. ChIP assays were performed using (C)  
293 anti-acetylated histone H3, (D) anti-acetylated histone H4, (E) anti-CBP, (F) anti-p300,  
294 or normal IgG. ChIP signals were detected using real-time qPCR with primers for the  
295 designated promoter regions of *Ggt*. Values are expressed as means  $\pm$  standard error of  
296 the mean (n = 6–7). \*\*\*  $P < 0.001$ ; \*\*  $P < 0.01$ ; \*  $P < 0.05$ , significantly different from  
297 the control group (Student's t-test). Control, control rats treated with vehicle; STZ,  
298 moderate hypoinsulinemic rats treated with streptozotocin.  
299

